In vitro antimalarial activity of tigecycline against Plasmodium falciparum culture-adapted reference strains and clinical isolates from the Brazilian Amazon

Introduction: We evaluated the in vitro antimalarial activity of tigecycline as an alternative drug for the treatment of severe malaria. Methods: A chloroquine-sensitive Plasmodium falciparum reference strain, a chloroquine-resistant reference strain, and three clinical isolates were tested for in vitro susceptibility to tigecycline. A histidine-rich protein in vitro assay was used to evaluate antimalarial activity. Results: The geometric-mean 50% effective concentration (EC50%) of tigecycline was 535.5 nM (confidence interval (CI): 344.3-726.8). No significant correlation was found between the EC50% of tigecycline and that of any other tested antimalarial drug. Conclusions: Tigecycline may represent an alternative drug for the treatment of patients with severe malaria.

引言：本研究评估了替加环素（tigecycline）作为重症疟疾备选治疗药物的体外抗疟活性。方法：选取氯喹敏感型恶性疟原虫（Plasmodium falciparum）参考毒株、氯喹耐药型参考毒株及3株临床分离株，检测其对替加环素的体外药敏性；本研究采用富组氨酸蛋白体外检测法评估抗疟活性。结果：替加环素的几何平均半数有效浓度（50% Effective Concentration，EC50%）为535.5 nM，置信区间（confidence interval，CI）为344.3~726.8。未发现替加环素的EC50%与其余受试抗疟药物的EC50%存在显著相关性。结论：替加环素可作为重症疟疾患者的备选治疗药物。